Kawano Michitaka, Kaino Seiji, Amano Shogo, Shinoda Shuhei, Suenaga Shigeyuki, Sen-Yo Manabu, Sakaida Isao
Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
In Vivo. 2018 May-Jun;32(3):637-642. doi: 10.21873/invivo.11286.
BACKGROUND/AIM: Gemcitabine (GEM) sensitivity can help select the appropriate treatment for pancreatic cancer. We examined the association between HSP27 expression and GEM sensitivity.
A total of 19 patients with unresectable pancreatic cancer who underwent endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) were enrolled and treated with GEM alone. We measured the expression of heat shock protein 27 (HSP27) and phosphorylated HSP27(p-HSP27) in EUS-FNA samples and evaluated the effects of GEM treatment.
The rate of GEM resistance was significantly higher in patients who showed overexpression of p-HSP27 (p<0.05). When we set the cut-off p-HSP27 (Ser82) detection rate at 51.6%, the group with a detection rate of >51.6% showed a significantly lower survival rate, and GEM was administered for a shorter period of time (p<0.05).
It was suggested that the HSP27 expression in EUS-FNA samples was useful for predicting GEM sensitivity.
背景/目的：吉西他滨（GEM）敏感性有助于为胰腺癌选择合适的治疗方法。我们研究了热休克蛋白27（HSP27）表达与GEM敏感性之间的关联。
共纳入19例接受内镜超声引导下细针穿刺活检（EUS-FNA）的不可切除胰腺癌患者，仅接受GEM治疗。我们测量了EUS-FNA样本中热休克蛋白27（HSP27）和磷酸化HSP27（p-HSP27）的表达，并评估了GEM治疗的效果。
p-HSP27过表达的患者中GEM耐药率显著更高（p<0.05）。当我们将p-HSP27（Ser82）检测率的临界值设定为51.6%时，检测率>51.6%的组生存率显著更低，且GEM给药时间更短（p<0.05）。
提示EUS-FNA样本中的HSP27表达有助于预测GEM敏感性。
